Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.
Multiple sclerosis: an immune or neurodegenerative disorder?
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
CNS myelin wrapping is driven by actin disassembly.
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
Treatment of neuromyelitis optica.
Laquinimod in multiple sclerosis.
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder.
Imaging outcomes for trials of remyelination in multiple sclerosis.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
Analysis: Healthy babies born after accelerated elimination of teriflunomide
4-aminopyridine toxicity: a case report and review of the literature.
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Dynamic regulatory network controlling TH17 cell differentiation.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
Multiple sclerosis.
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Application of fullerenes in nanomedicine: an update.
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.

Pages